Profilo
Philip Ruan is a member of GT’s Corporate & Securities Practice, focusing on China-related transactions including venture capital, M&A and collaborative deals, with a focus on the life science industry. Philip also advises clients over China-related regulatory matters regarding foreign exchange, data, anti-bribery, etc.
Concentrations
- M&A
- PE & VC Investment
- JV & Technology Collaboration
Competenze
Esperienze Professionali - Attività Accademiche
- Assisted BP in creation of multiple joint ventures in China
- Assisted Castrol in collaborations with auto makers and service providers in China
- Assisted in a cross-border technology transfer transaction for multiple China-based pharmaceutical company as licensee
- Assisted several US companies in managing its IP portfolio and IP enforcement in China
- Advised Tuscan Holding Corp in its de-SPAC transaction with Microvast
- Advised SJL Partners, KCC and Wonik in connection with the matters relating to their US$3.1 billion acquisition of MPM Holdings (Momentive), a leading global specialty chemicals and materials company based in Waterford, NY, handling post-closing corporate restructuring and business integration (including in mainland China, Taiwan, Japan and Singapore)
- Advised on post-closing corporate restructuring (including in Japan, mainland China, Hong Kong) for Quaker Houghton, a global supplier of industrial process fluids
- Represented Medtronic is divesting its subsidiary Beijing Libeier Bio-engineering Institute , Ltd. to AK Medical International Limited, a HK listed company at the price of US$ 40.2 million
- Advised Volvo CE in its divestiture of NHL
- Assisted a US investor in acquisition of another US company’s agrichemical business, and associated asset transfer in China
- Assisted Volvo CE in acquisition of Terex, a UK-based company’s off-road hauler business, conducting due diligence on the target’s Chinese business and assisted in CSRC filing
- Advised a RMB fund on its USD10 million preferred stock investment in a US startup specialized in the reagents and services of next generation sequencing
- Advised a USD fund on its RMB90 million preferred stock investment in a China-based manufacturer of orthopedics products
- Advised a USD fund on its USD15 million preferred stock investment in a China-based provider of pharmacy benefit manager services
- Advised a RMB fund on its USD10 million preferred stock investment in a China-based intraocular lens manufacturer
- Assisted a USD fund in its USD25 million preferred stock investment in a China-based traditional Chinese medicine service provider
- Advised a Chinese fund on a 6 million preferred stock investment in a medical device manufacturer in China
- Advised a US fund on a 90 million RMB preferred stock investment in a hospital management company in China
- Advised a US fund on a 20 million USD preferred stock investment in a vaccine producer in China
- Advised a Korean fund on a 5 million USD convertible bond investment in a chain hotel company in China
Formazione
Formazione
- LL.M., Harvard Law School
- LL.M., Fudan University School of Law
- LL.B., Shanghai International Studies University School of Law
Abilitazioni
- New York
- Passed national PRC judicial qualification examination
Lingue
- Chinese (Mandarin)
- Inglese